Ocugen Inc. Finalizes Merger Agreement with Carisma Therapeutics, Inc., Including a $5 Million Investment in Common Stock
Reuters
Sep 06
<a href="https://laohu8.com/S/OCGN">Ocugen</a> Inc. Finalizes Merger Agreement with <a href="https://laohu8.com/S/CARM">Carisma Therapeutics</a>, Inc., Including a $5 Million Investment in Common Stock
Ocugen Inc. has announced a significant update in its merger and acquisition activities involving its wholly-owned subsidiary, OrthoCellix, Inc. According to the company, OrthoCellix will merge with Azalea Merger Sub, Inc., resulting in OrthoCellix becoming a wholly-owned subsidiary of Carisma Therapeutics Inc. This arrangement is part of a broader agreement that also involves a planned Concurrent Investment, where Carisma and OrthoCellix will seek investments from designated investors, aiming for gross proceeds of at least $25 million. Ocugen has committed to purchasing shares of Carisma common stock as part of this investment. Carisma will also enter into a registration rights agreement to facilitate the resale of certain shares of common stock held by investors. The transaction is expected to be completed following the satisfaction of customary conditions.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ocugen Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-087801), on September 05, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.